ERBB2 and breast cancer: In another study of 373 patients with breast cancer followed for a mean of 2.4 ± 1 years, there were no cases of LV dysfunction in the anthracycline cohort (0/202), and 16/171 (9%) in the anti-HER2 therapy group (21).